<DOC>
	<DOCNO>NCT00405730</DOCNO>
	<brief_summary>To evaluate safety efficacy Nepafenac 1 mg/ml Eye Drops , Suspension , compare Placebo Ketorolac Trometamol 5 mg/ml Eye Drops , Solution prevention treatment ocular inflammation ocular pain cataract extraction IOL implantation</brief_summary>
	<brief_title>Nepafenac 0.1 % Eye Drops , Suspension Compared Ketorolac Trometamol 0.5 % Eye Drops , Solution Placebo</brief_title>
	<detailed_description />
	<mesh_term>Cataract</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ketorolac</mesh_term>
	<mesh_term>Ketorolac Tromethamine</mesh_term>
	<mesh_term>Nepafenac</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>Patients ( 18 year old ) race either sex , require cataract extraction plan implantation posterior chamber intraocular lens . Other protocoldefined inclusion criterion may apply . Under 18 . Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Cataracts</keyword>
</DOC>